Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1460-1468

  Sehested, Maxwell ^a   Wessel, Irene ^a   Jensen, Lars H ^a,c   Holm, Bente ^a   Oliveri, Roberto S ^a   Kenwrick, Sue ^b,d   Creighton, Andrew M ^b,e   Nitiss, John L ^c   Jensen, Peter B ^a  

^a Rigshospitalet   (Denmark)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; PIPERAZINE DERIVATIVE; RAZOXANE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHO CELL; GENE MUTATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; ISOENZYMES; MOLECULAR SEQUENCE DATA; MUTATION; PIPERAZINES; RAZOXANE; SACCHAROMYCES CEREVISIAE;

EID: 0032054222     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
2. Wasserman, R. A., and Wang, J. C. Analysis of yeast DNA topoisomerase-II mutants resistant to the antitumor drug amsacrine. Cancer Res., 54: 1795-1800, 1994.
3. Jensen, P. B., Jensen, P. S., Demant, E. J. F., Friche, F., Sørensen, B. S., Sehested, M., Wassermann, K., Vindeløv, L., Westergaard, O., and Hansen, H. H. Antagonistic effect of aclarubicin on daunorubicin induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res., 51: 5093-5099, 1991.
4. Drake, F. H., Hofmann, G. A., Mong, S-M., Batrus, J. L., Hertzberg, R. P., Johnson, R. K., Mattern, M. R., and Mirabelli, C. K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res., 49: 2578-2583, 1989.
5. Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R. C., and Fry, D. W. Inhibition of type II topoisomerase by fostriecin. Biochem. Pharmacol., 37: 4063-4068, 1988.
6. Jensen, P. B., Sørensen, B. S., Sehested, M., Grue, P., Demant, E. J. F., and Hansen, H. H. Targeting the cytotoxicity of topoisomerase II directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res., 54: 2959-2963, 1994.
7. Tanabe, K., Ikegami, Y., Ishida, and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2.6-dioxopiperazine) derivatives. Cancer Res., 51: 4903-4908, 1991.
8. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
9. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA, 91: 1781-1785, 1994.
10. Roca, J., and Wang, J. C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 77: 609-616, 1994.
11. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 57: 879-886, 1996.
12. Ishida, R., Hamatake, M., Wasserman, R. A., Nitiss, J. L., Wang, J. C., and Andoh, T. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res., 55: 2299-2303, 1995.
13. Fattman, C. L., Allan, W. P., Hasinoff, B. B., and Yalowich J. C. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem. Pharmacol., 52: 635-642, 1996.
14. Davies, S. L., Bergh, J., Harris, A. L., and Hickson, I. D. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br. J. Cancer, 75: 816-821, 1997.
15. Hasinoff, B. B., Kuschak, T. I., Creighton, A. M., Fattman, C. L., Allan, W. P., Thampatty, P., and Yalowich, J. C. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem. Pharmacol., 53: 1843-1853, 1997.
16. Holm, B., Jensen, P. B., and Sehesled, M. ICRF-187 rescue in etoposide (VP-16) treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol., 38: 203-209, 1996.
17. Jensen, P. B., and Sehested, M. DNA topoisomerase II rescue by catalytic inhibitors. A new strategy to improve the antitumor selectivity of etoposide. Biochem. Pharmacol., 54: 755-759, 1997.
18. Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M. Sanger, J., Kramer, E., Ferrans, V., Hochster, H., Meyers, M., Blum, R. H., Feit, F., Attubato, M., Burrows, W., and Muggia, F. M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10: 117-127, 1992.
19. Kenwrick, S. J., and Creighton, A. M. Isolation and characterization of a subline of CHO cells with induced resistance to ICRF 159. Br. J. Cancer, 46: 504-505, 1982.
20. Kenwrick, S. J. Studies on the mechanism of induced resistance to antitumor agent ICRF-159 in mammalian cell lines (Thesis). London: University of London, 1984.
21. Creighton, A. M. U. S. Patent 3,941,790, pp. 4-5, 1976.
22. Jensen, P. B., Christensen, I. J., Sehested, M., Hansen, H. H., and Vindeløv, L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br. J. Cancer, 67: 311-320, 1993.
23. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Techniques, pp. 379-401. New York: Marcel Dekker Inc., 1981.
24. 2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays. Anal. Biochem., 168: 88-93, 1988.
25. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49: 58-62, 1989.
26. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
27. r 170,000 isozyme of DNA topoisomerase-II in human tumor cells. Cancer Res., 53: 1373-1379, 1993.
28. Chan, V. T. W., Ng, S., Eder, J. P., and Schipper, L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem., 268: 2160-2165, 1993.
29. Hsiung, Y., Jannatipour, M., Rose, A., McMahon, J., Duncan, D., and Nitiss, J. L. Functional expression of human topoisomerase II a in yeast: mutations at amino acids 450 or 803 of topoisomerase II α result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res., 56: 91-99, 1996.
30. Sehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E., and Demant, E. J. F. Antagonistic effect of the cardioprotector (+)-1,2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
31. Nitiss, J. L., and Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
32. Jensen, P. B., Sørensen, B. S., Sehested, M., Demant, E. J. F., Kjeldsen, E., Friche, E., and Hansen, H. H. Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem. Pharmacol., 45: 2025-2035, 1993.
33. Jensen, S., Andersen, A. H., Kjeldsen, E., Biersack, H., Olsen, E. H. N., Andersen, T. B., Westergaard, O., and Jakobsen, B. K. Analysis of functional domain organization in DNA topoisomerase II from humans. Mol. Cell. Biol., 16: 3866-3877, 1996.
34. Vassetzky, V. S., Alghisi, G-C., and Gasser, S. M. DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays, 17: 767-774, 1995.
35. Nitiss, J. L. Mutational analysis of topoisomerase II drug action: the yeast test tube. Anticancer Drugs, 7 (Suppl. 3): 27-34, 1996.
36. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
37. Wigley, D. B., Davies, G. J., Dodson, E. J., Maxwell, A., and Dodson, G. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature (Lond.), 351: 624-629, 1991.
38. Tingey, A. P., and Maxwell, A. Probing the role of the ATP-operated clamp in the strand-passage reaction of DNA gyrase. Nucleic Acids Res., 24: 4868-4873, 1996.